What's Happening?
Cresilon, a biotechnology company based in Brooklyn, has been awarded an Innovative Technology contract by Vizient for its hemostatic gel, TRAUMAGEL. This contract was granted following a review by hospital experts on Vizient's client-led councils, highlighting
the gel's potential to improve healthcare outcomes. TRAUMAGEL, which utilizes Cresilon's proprietary hydrogel technology, is designed to stop bleeding rapidly and is the first gel in a syringe approved by the U.S. FDA for temporary external use to control moderate to severe bleeding. The product is supplied in a 30 mL sterile prefilled syringe, requiring no preparation, and is easy to apply and remove. This contract will increase access to TRAUMAGEL for medical professionals across the United States, potentially setting a new standard in hemorrhage control.
Why It's Important?
The awarding of the Innovative Technology contract to Cresilon for TRAUMAGEL is significant as it underscores the product's potential to revolutionize hemorrhage control in medical settings. By providing a rapid and effective solution for bleeding, TRAUMAGEL can enhance patient safety and clinical care, which is crucial in trauma and surgical environments. The contract with Vizient, a major healthcare performance improvement company, also means that TRAUMAGEL will be more widely available to healthcare providers, potentially leading to broader adoption and improved patient outcomes. This development could also position Cresilon as a leader in the hemostatic medical device market, influencing future innovations and standards in the industry.
What's Next?
With the Innovative Technology contract in place, Cresilon is poised to expand the reach of TRAUMAGEL across the United States. The company will likely focus on increasing production and distribution to meet the anticipated demand from healthcare providers. Additionally, Cresilon may engage in further research and development to enhance its product line and explore new applications for its hydrogel technology. The success of TRAUMAGEL could also attract interest from investors and partners, potentially leading to strategic collaborations or expansions into new markets.
